Summary: New research indicates that GLP-1 receptor agonists—medications such as Ozempic and Wegovy—may substantially reduce behaviors associated with violence. An analysis of a nationally representative 2025 survey of U.S. adults found that current GLP-1 use weakened the established link between high impulsivity and violent behavior by about 62% and reduced the association between alcohol use and violence by roughly 52%.
The authors suggest these metabolic medications may act in a manner similar to cognitive behavioral therapy (CBT), lengthening the psychological interval between an aggressive impulse and a physical response. The study points to a potential new area of inquiry for public safety and behavioral neuroscience.
Key Facts
- Behavioral moderation: GLP-1 receptor agonists, prescribed mainly for type 2 diabetes and obesity, appear to alter neural pathways involved in reward, motivation and impulse control—pathways that are also implicated in violent conduct.
- 62% reduction in impulsive action link: The well-documented association between trait impulsivity and violent acts was about 62% weaker among current GLP-1 users compared with former users in the study sample.
- About 52% reduction for alcohol-related violence: Current GLP-1 use corresponded to an approximately 52% weaker relationship between alcohol consumption and violent offenses, although this result was less consistent across sensitivity checks.
- CBT-like effect: Researchers and neuroscientists describe the medications as weakening the immediate path from impulse to action—functionally similar to how CBT trains a person to pause and choose a different response.
- Scope and limitations: The analysis used data from a 2025 U.S. survey of 7,521 adults, focusing on 821 individuals who reported lifetime GLP-1 use. The design was cross-sectional and observational, so causal claims cannot be made without further longitudinal and experimental research.
Source: Rutgers University
Overview
Researchers from Rutgers analyzed whether GLP-1 receptor agonist use moderates the influence of impulsivity and alcohol use on violent criminal behavior. The results, published in the journal Criminology, show that current users of GLP-1 medications reported substantially weaker links between known behavioral risk factors—especially impulsivity—and self-reported violent actions such as fighting, assault and robbery.
The primary sample included 7,521 U.S. adults surveyed in 2025, with focused analyses on 821 respondents who had ever used a GLP-1 medication. Within that subgroup, 597 were current users and 224 were former users. Violent behavior was measured using a validated self-report offending scale that captures a range of aggressive and criminal acts.
“The strongest finding in the study was that the well-established link between impulsivity and violent behavior was substantially weaker among current GLP-1 users compared to former users,” said Daniel Semenza, lead author and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health. “As GLP-1 drugs become increasingly widespread, it is important to understand all of their potential behavioral effects, including those relevant to public safety.”
Coauthor Christopher Thomas, an assistant professor at Rutgers University–Camden, added: “Our findings are consistent with these medications working like cognitive behavioral therapy—weakening the path from impulse to action rather than eliminating impulsivity itself.”
Although the associations between impulsivity, alcohol use and violent behavior were strong overall, the interactions with current GLP-1 use indicated meaningful attenuation. The impulsivity–violence interaction was robust across sensitivity analyses, while the alcohol–violence interaction showed more variability in robustness tests.
The authors emphasize that the study’s cross-sectional and observational design prevents definitive causal interpretation. They call for longitudinal studies and controlled experiments to confirm whether GLP-1 medications causally reduce violence risk and to clarify the underlying neurological and behavioral mechanisms.
Key Questions Answered:
A: GLP-1 receptors are present not only in the gut but also in brain regions that control reward processing, dopamine signaling, motivation and impulse regulation, including the striatum and prefrontal cortex. By modulating these neural circuits, GLP-1 agonists can change how the brain processes immediate rewards and urges, which may dampen compulsive drives tied to food, substances or sudden aggressive outbursts.
A: CBT trains people to recognize and pause before acting on harmful impulses. The study suggests GLP-1 drugs may produce a similar functional effect by chemically reducing the immediacy of the impulse-to-action pathway. That does not mean these medications erase a person’s impulsive tendencies, but they may create a short window that allows different behavioral choices.
A: No. The Rutgers analysis is cross-sectional and observational, capturing a single point in time. It cannot establish cause and effect. The authors stress the need for long-term clinical trials and longitudinal research before drawing policy conclusions about population-level effects on crime.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The full journal paper was reviewed for accuracy.
- Additional context was provided by editorial staff to clarify methodology and limitations.
About this neuropharmacology and violence research news
Author: Patrice Harley
Source: Rutgers University
Contact: Patrice Harley – Rutgers University
Image credit: Neuroscience News
Original research: Open access. “GLP-1 receptor agonist use and violent crime among US adults” by Daniel C. Semenza and Christopher Thomas. Criminology. DOI: 10.1111/1745-9125.70058
Abstract
GLP-1 receptor agonist use and violent crime among US adults
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a drug class widely used for diabetes and obesity, have shown emerging influences on substance use, reward processing and impulse control. This study evaluates whether current GLP-1 RA use moderates behavioral pathways from impulsivity and alcohol use to violent crime.
Data derive from a nationally representative 2025 U.S. survey (n = 7,521), including 821 respondents reporting lifetime GLP-1 RA use. Negative binomial regression models with overlap weighting compared current users (n = 597) and former users (n = 224) on self-reported violent criminal behavior in the past year.
While impulsivity and alcohol use were strongly associated with violent criminality overall, those associations were significantly weaker among current GLP-1 RA users (GLP-1 RA × impulsivity incidence rate ratio (IRR) = 0.38, p = 0.002; GLP-1 RA × alcohol use IRR = 0.48, p = 0.023). Robustness checks consistently supported the interaction with impulsivity, while evidence for the alcohol interaction was less consistent.
These results suggest GLP-1 RAs may attenuate behavioral risk mechanisms—particularly impulsivity—linked to aggression, raising novel biosocial hypotheses about pharmacological influences on violent behavior. Future longitudinal and experimental research should confirm these findings and investigate causal mechanisms.